Mabwell Expands MAIWEIJIAN Indications with NMPA Approval for Bone Metastases

Event summary

  • Mabwell's MAIWEIJIAN (Denosumab Injection) received NMPA approval for additional indications in bone metastases from solid tumors and multiple myeloma on May 20, 2026.
  • MAIWEIJIAN is a first-tier biosimilar of Xgeva®, initially approved in March 2024 for treating unresectable giant cell tumor of bone.
  • The product has secured registration approval in Pakistan and has cooperation agreements in 33 countries, with submissions in 8 additional nations.
  • Clinical studies in top-tier journals confirmed MAIWEIJIAN's efficacy and safety, positioning it as a superior alternative to bisphosphonates.

The big picture

Mabwell's NMPA approval for MAIWEIJIAN's expanded indications strengthens its position in the biosimilar market, particularly in oncology. The approval aligns with global trends favoring targeted therapies over traditional treatments like bisphosphonates. Mabwell's strategic focus on both domestic and international regulatory pathways underscores its ambition to become a key player in the biopharmaceutical industry.

What we're watching

Market Expansion
How Mabwell will leverage its first-mover advantage in China and international markets to drive MAIWEIJIAN's commercial success.
Regulatory Momentum
Whether the NMPA approval will accelerate approvals in other countries, particularly those with pending submissions.
Competitive Positioning
The pace at which Mabwell can differentiate MAIWEIJIAN from Xgeva® and other bisphosphonates in clinical and commercial settings.